Mandate

Vinge advises Axcel and XPartners in connection with the acquisition of B&B Bro & Betong

November 16, 2023 Real Estate and Construction M&A

Vinge has advised Axcel VII (“Axcel”) and XPartners Samhällsbyggnad (”XPartners”) in connection with the acquisition of B&B Bro & Betong Projektledning AB (”B&B Bro & Betong”).

B&B Bro & Betong is a consulting company that offers qualified project and construction management services within infrastructure and urban development. The services include several stages of the construction process such as feasibility studies, investigations, system documents, construction documents, production and handover, and the company works actively with continuous improvements and follows ISO requirements for quality and environmental management. B&B Bro & Betong participates in many of Mälardalen’s major societally important infrastructure projects and clients include the City of Stockholm, Ports of Stockholm, the Swedish Transport Administration and the new metro.

Vinge's team consisted of partner Christina Kokko together with Karl Klackenberg, Carl Fredrik Wachtmeister, Egil Svensson, Sara Passandideh and Alexander Rüdén (M&A), Clara Klingspor (Construction) and Cecilia Loctander (Transaction Support Co-ordinator).

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026